DNDi Strategy

DNDi Strategy

Attention: open in a new window.

DNDi Strategy

WHAT IS DNDi DOING TO ADDRESS UNMET TREATMENT NEEDS?

Short term: better use of existing treatments

Nifurtimox-eflornithine combination therapy (NECT), the simplified treatment for stage 2 HAT, now in use

Medium term: drug candidates identified through compound mining

Fexinidazole: first oral new drug candidate entered clinical development from the Nitroimidazoles Project

Long term: discovery of promising new drug candidates and improved clinical research capacity

New drugs developed from compounds identified (i.e. oxaboroles) in discovery research and progressed through HAT lead optimization consortium to pre-clinical
Multi-country, multi-partner HAT Platform to strengthen regional research capacity
Back-up nitroimidazoles and oxaboroles

By 2014, DNDi aims to deliver from its HAT-specific portfolio:

Except where otherwise noted, content on this site is licensed under
a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License